This post was originally published on this site
https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEG4L0DO_L.jpg“The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion,” the Swiss drug maker said in a statement. “The Roche nanopore sequencer, once developed, will utilise a novel approach that combines electronic and biological components to sequence DNA for fast, flexible and cost-effective clinical diagnostic testing.”
Financial details of the agreement were not disclosed.